The European Commission has granted marketing authorization for Vyepti (eptinezumab) in the European Union for the prophylactic treatment of migraine in adults who have at least four migraine days per month.
The approval, granted to Danish CNS specialist Lundbeck (LUND: CO), follows the positive opinion on November 11, 2021 from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). Vyepti is the first and only approved IV treatment for migraine prevention in the EU. The marketing authorization for Vyepti is an important step to increase Lundbeck’s global footprint, the company stated, and it is an important building block in the corporate strategy of Expand and Invest to Grow.
The marketing authorization is based on the efficacy and safety of Vyepti, which has been investigated in two phase III clinical trials (PROMISE-1 in episodic migraine and PROMISE-2 in chronic migraine). The clinical trial program demonstrated a reduction in monthly migraine days over placebo, which was sustained for the 12-week dosing interval, and for the duration of treatment (12 months in PROMISE-1 and six months in PROMISE-2). A reduction in prevalence of migraine of about 50% was observed for both doses of Vyepti on day 1 post-infusion. Effects on patient-reported outcomes were observed for up to 96 weeks. Also, the efficacy of Vyepti in migraine was demonstrated in patients with a dual diagnosis of chronic migraine and medication overuse headache (MOH) from the PROMISE-2 study.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze